Project Grant K99HL175185
- This Project Grant award of $473,096 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at the University of Utah to understand the role of lactate oxidation in the mitochondria of cardiomyocytes and its impact on cardiac function in heart failure. The key objectives are to: 1) Quantify direct versus indirect mitochondrial lactate oxidation in healthy and failing hearts; 2) Determine if mitochondrial localized MCT1 is necessary...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $238,008 to the University of Utah to study the role of lactate export in the progression of myelofibrosis, a type of myeloproliferative neoplasm. The research aims to investigate how inhibiting the lactate transporter MCT4 can prevent the differentiation of mesenchymal stromal cells into pro-fibrotic myofibroblasts, a key driver of fibrosis in myelofibrosis....
- This federal Project Grant award, valued at $385,000.00, is funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research aimed at understanding the role of mitochondrial magnesium (MMg2+) in regulating mitochondrial calcium (MCa2+) uptake and its impact on mitochondrial permeability transition pore (MPTP) opening during ischemic reperfusion injury. The research, conducted by the Rowan University...
- This federal Project Grant award of $618,126.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to elucidate the molecular mechanisms by which the cytokine interleukin-6 (IL-6) signaling triggers electrical changes in cardiac cells that can lead to life-threatening ventricular tachyarrhythmias, particularly in conditions of obesity. The research aims to determine the anti-arrhythmic efficacy of inhibiting IL-6 signaling...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,088,500.00 to The University of Iowa to conduct research related to genetic and molecular mechanisms of heart disease. The key objectives include: Defining microRNA (miR) targeting events and their biological relevance in the heart, as well as understanding the clinical significance of SNPs that alter cardiovascular miR functions. This involves...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $771,750 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism after myocardial infarction. The project aims to shed novel insights into how macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and lead to decreased NAD pools, which play a critical...
- This $540,927 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at the University of Mississippi Medical Center to investigate the brain's melanocortin-4 receptor (MC4R) system as a potential therapeutic target for ischemic heart disease and myocardial infarction. The 5-year project aims to determine how activating the brain's leptin-MC4R pathway influences brown adipose tissue activity, and whether this...
- This $242,250 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will fund a feasibility study to assess the use of coronary sinus blood sampling to measure changes in metabolite utilization during submaximal exercise in patients with heart failure. The study aims to implement arteriovenous sampling of the heart and leg to determine regional metabolic changes, with the goal of better understanding exercise limitations in...
- The University of Utah was awarded a $654,530 project grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to study the role of the serine-threonine kinase SGK1 in cardiometabolic heart failure with preserved ejection fraction (CMET HFPEF). The 4-year project, beginning September 1, 2025, aims to investigate how cardiac-specific SGK1 regulates cellular metabolism and impacts the pathogenesis of the prevalent CMET HFPEF,...
- This federal Project Grant award of $614,431.51 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to quantitatively characterize lactate metabolism in the heart and test the hypothesis that myocardial lactate production and consumption is integral to cardiac health. The award, active from January 1, 2025 to December 31, 2027, aims to: 1) use isotope tracers to quantify lactate production and consumption...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $183,600.00 to the University of Utah to investigate metabolite transport modulation as a potential therapeutic approach to mitigate ischemic-reperfusion (I/R) injury in the heart. The research aims to define metabolite transport and utilization in response to I/R with and without inhibition of the monocarboxylate transporter 4 (MCT4), determine the impact of MCT4 inhibition on metabolite transport in vivo during I/R injury, test whether MCT4 inhibition can protect against the development of ischemic cardiomyopathy, and evaluate the role of MCT4 inhibition in preserving human myocardium in ex vivo injury models. The award period is from September 19, 2025 to August 31, 2027. This research seeks to uncover how MCT4 inhibition influences myocardial biology, offering a potential therapeutic approach to alleviate cardiac injury and advance cardiovascular medicine.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $183.6k | 9/18/25 |